ABSTRACT
The complement system is the first defense line of the immune system. However, pathogens have evolved numerous strategies to evade complement attacks. Streptococcus suis is an important zoonotic bacterium, harmful to both the pig industry and human health. ApuA has been reported as a bifunctional amylopullulanase and also contributed to virulence of S. suis. Herein, we found that ApuA could activate both classical and alternative pathways of the complement system. Furthermore, by using bacterial two-hybrid, far-western blot and ELISA assays, it was confirmed that ApuA could interact with complement C3b. The interaction domain of ApuA with C3b was found to be its α-Amylase domain (ApuA_N). After construction of an apuA mutant (ΔapuA) and its complementary strain, it was found that compared to the wild-type strain (WT), ΔapuA had significantly increased C3b deposition and membrane attack complex formation. Additionally, ΔapuA showed significantly lower survival rates in human serum and blood and was more susceptible to engulfment by neutrophils and macrophages. Mice infected with ΔapuA had significantly higher survival rates and lower bacterial loads in their blood, lung and brains, compared to those infected with WT. In summary, this study identified ApuA as a novel factor involved in the complement evasion of S. suis and suggested its multifunctional role in the pathogenesis of S. suis.
Subject(s)
Bacterial Proteins , Complement C3b , Immune Evasion , Streptococcal Infections , Streptococcus suis , Streptococcus suis/pathogenicity , Streptococcus suis/genetics , Streptococcus suis/immunology , Streptococcus suis/enzymology , Animals , Complement C3b/immunology , Mice , Streptococcal Infections/immunology , Streptococcal Infections/veterinary , Streptococcal Infections/microbiology , Humans , Bacterial Proteins/genetics , Bacterial Proteins/metabolism , Bacterial Proteins/immunology , Glycoside Hydrolases/genetics , Glycoside Hydrolases/metabolism , Female , VirulenceABSTRACT
Developing an effective Staphylococcus aureus (S. aureus) vaccine has been a challenging endeavor, as demonstrated by numerous failed clinical trials over the years. In this study, we formulated a vaccine containing a highly conserved moonlighting protein, the pyruvate dehydrogenase complex E2 subunit (PDHC), and showed that it induced strong protective immunity against epidemiologically relevant staphylococcal strains in various murine disease models. While antibody responses contributed to bacterial control, they were not essential for protective immunity in the bloodstream infection model. Conversely, vaccine-induced systemic immunity relied on γδ T cells. It has been suggested that prior S. aureus exposure may contribute to the reduction of vaccine efficacy. However, PDHC-induced protective immunity still facilitated bacterial clearance in mice previously exposed to S. aureus. Collectively, our findings indicate that PDHC is a promising serotype-independent vaccine candidate effective against both methicillin-sensitive and methicillin-resistant S. aureus isolates.
Subject(s)
Staphylococcal Infections , Staphylococcal Vaccines , Staphylococcus aureus , Animals , Staphylococcal Infections/prevention & control , Staphylococcal Infections/immunology , Staphylococcal Infections/microbiology , Mice , Staphylococcus aureus/immunology , Staphylococcus aureus/enzymology , Staphylococcal Vaccines/immunology , Pyruvate Dehydrogenase Complex/metabolism , Pyruvate Dehydrogenase Complex/immunology , Female , Antibodies, Bacterial/immunology , Disease Models, Animal , Humans , Bacterial Proteins/immunology , Bacterial Proteins/metabolism , Mice, Inbred C57BL , Methicillin-Resistant Staphylococcus aureus/immunology , Pyruvate Dehydrogenase (Lipoamide)/immunology , Pyruvate Dehydrogenase (Lipoamide)/metabolism , Pyruvate Dehydrogenase (Lipoamide)/geneticsABSTRACT
Acinetobacter baumannii is a gram-negative bacillus prevalent in nature, capable of thriving under various environmental conditions. As an opportunistic pathogen, it frequently causes nosocomial infections such as urinary tract infections, bacteremia, and pneumonia, contributing to increased morbidity and mortality in clinical settings. Consequently, developing novel vaccines against Acinetobacter baumannii is of utmost importance. In our study, we identified 10 highly conserved antigenic proteins from the NCBI and UniProt databases for epitope mapping. We subsequently screened and selected 8 CTL, HTL, and LBL epitopes, integrating them into three distinct vaccines constructed with adjuvants. Following comprehensive evaluations of immunological and physicochemical parameters, we conducted molecular docking and molecular dynamics simulations to assess the efficacy and stability of these vaccines. Our findings indicate that all three multi-epitope mRNA vaccines designed against Acinetobacter baumannii are promising; however, further animal studies are required to confirm their reliability and effectiveness.
Subject(s)
Acinetobacter baumannii , Bacterial Vaccines , Computational Biology , Acinetobacter baumannii/immunology , Acinetobacter baumannii/genetics , Bacterial Vaccines/immunology , Bacterial Vaccines/genetics , Computational Biology/methods , Epitopes/immunology , Epitopes/chemistry , Molecular Docking Simulation , Acinetobacter Infections/prevention & control , Acinetobacter Infections/immunology , Epitope Mapping , mRNA Vaccines , Molecular Dynamics Simulation , Humans , RNA, Messenger/genetics , RNA, Messenger/immunology , Antigens, Bacterial/immunology , Antigens, Bacterial/genetics , Bacterial Proteins/immunology , Bacterial Proteins/genetics , Bacterial Proteins/chemistryABSTRACT
Pseudomonas aeruginosa is a complex nosocomial infectious agent responsible for numerous illnesses, with its growing resistance variations complicating treatment development. Studies have emphasized the importance of virulence factors OprE and OprF in pathogenesis, highlighting their potential as vaccine candidates. In this study, B-cell, MHC-I, and MHC-II epitopes were identified, and molecular linkers were active to join these epitopes with an appropriate adjuvant to construct a vaccine. Computational tools were employed to forecast the tertiary framework, characteristics, and also to confirm the vaccine's composition. The potency was weighed through population coverage analysis and immune simulation. This project aims to create a multi-epitope vaccine to reduce P. aeruginosa-related illness and mortality using immunoinformatics resources. The ultimate complex has been determined to be stable, soluble, antigenic, and non-allergenic upon inspection of its physicochemical and immunological properties. Additionally, the protein exhibited acidic and hydrophilic characteristics. The Ramachandran plot, ProSA-web, ERRAT, and Verify3D were employed to ensure the final model's authenticity once the protein's three-dimensional structure had been established and refined. The vaccine model showed a significant binding score and stability when interacting with MHC receptors. Population coverage analysis indicated a global coverage rate of 83.40%, with the USA having the highest coverage rate, exceeding 90%. Moreover, the vaccine sequence underwent codon optimization before being cloned into the Escherichia coli plasmid vector pET-28a (+) at the EcoRI and EcoRV restriction sites. Our research has developed a vaccine against P. aeruginosa that has strong binding affinity and worldwide coverage, offering an acceptable way to mitigate nosocomial infections.
Subject(s)
Computational Biology , Pseudomonas Infections , Pseudomonas aeruginosa , Sepsis , Pseudomonas aeruginosa/immunology , Pseudomonas aeruginosa/genetics , Humans , Pseudomonas Infections/prevention & control , Pseudomonas Infections/immunology , Pseudomonas Infections/microbiology , Sepsis/prevention & control , Sepsis/immunology , Sepsis/microbiology , Computational Biology/methods , Epitopes/immunology , Epitopes/chemistry , Pneumonia/prevention & control , Pneumonia/immunology , Pneumonia/microbiology , Pseudomonas Vaccines/immunology , Bacterial Vaccines/immunology , Bacterial Proteins/immunology , Bacterial Proteins/geneticsABSTRACT
We compared the immunogenicity of recombinant S. pneumoniae pneumolysin (rPly) when administered with and without Al(OH)3 adjuvant, and evaluated the protective properties of recombinant protein in the active defense experiment. It was shown that double immunization with rPly+Al(OH)3 increases the levels of IgG antibodies in comparison with the control (p<0.01), while triple immunization results in a more significant increase in IgG antibody levels (p<0.001). Double immunization with rPly without Al(OH)3 does not induce a significant increase in antibody levels in comparison with the control, while triple immunization results in a slight but significant increase in antibody levels (p<0.05). The active defense test proved the protective activity of rPly against S. pneumoniae serotype 3 at intranasal infection.
Subject(s)
Antibodies, Bacterial , Bacterial Proteins , Immunoglobulin G , Recombinant Proteins , Streptococcus pneumoniae , Streptolysins , Streptolysins/immunology , Streptolysins/genetics , Bacterial Proteins/immunology , Bacterial Proteins/genetics , Streptococcus pneumoniae/immunology , Streptococcus pneumoniae/genetics , Animals , Recombinant Proteins/immunology , Recombinant Proteins/genetics , Antibodies, Bacterial/immunology , Antibodies, Bacterial/blood , Immunoglobulin G/immunology , Immunoglobulin G/blood , Mice , Pneumococcal Infections/immunology , Pneumococcal Infections/prevention & control , Pneumococcal Infections/microbiology , Adjuvants, Immunologic , Aluminum Hydroxide/immunology , Aluminum Hydroxide/administration & dosage , Pneumococcal Vaccines/immunology , Pneumococcal Vaccines/administration & dosage , FemaleABSTRACT
Live vaccines are ideal for inducing immunity but suffer from the need to attenuate their pathogenicity or replication to preclude the possibility of escape. Unnatural amino acids (UAAs) provide a strategy to engineer stringent auxotrophies, yielding conditionally replication incompetent live bacteria with excellent safety profiles. Here, we engineer Pseudomonas aeruginosa to maintain auxotrophy for the UAA p-benzoyl-L-phenylalanine (BzF) through its incorporation into the essential protein DnaN. In vivo evolution using an Escherichia coli-based two-hybrid selection system enabled engineering of a mutant DnaN homodimeric interface completely dependent on a BzF-specific interaction. This engineered strain, Pa Vaccine, exhibits undetectable escape frequency (<10-11) and shows excellent safety in naïve mice. Animals vaccinated via intranasal or intraperitoneal routes are protected from lethal challenge with pathogenic P. aeruginosa PA14. These results establish UAA-auxotrophic bacteria as promising candidates for bacterial vaccine therapy and outline a platform for expanding this technology to diverse bacterial pathogens.
Subject(s)
Pseudomonas Infections , Pseudomonas Vaccines , Pseudomonas aeruginosa , Animals , Pseudomonas aeruginosa/immunology , Pseudomonas aeruginosa/genetics , Pseudomonas Infections/prevention & control , Pseudomonas Infections/immunology , Pseudomonas Infections/microbiology , Mice , Female , Pseudomonas Vaccines/immunology , Pseudomonas Vaccines/genetics , Amino Acids , Phenylalanine/analogs & derivatives , Escherichia coli/immunology , Escherichia coli/genetics , Bacterial Proteins/immunology , Bacterial Proteins/genetics , Mice, Inbred BALB CABSTRACT
BACKGROUND: Brucellosis is an economically important infectious caused by most commonly by Brucella. Detection of infected animals at the early stage is important for controlling the disease. The diagnostic antigens, usually protein antigens, have attracted much interest. However, the accurate mechanism of immune response is still unknown. The secretory effectors (BPE005, BPE275, and BPE123) of the type IV secretion system (T4SS) were involved in the intracellular circulation process of Brucella and the immune responses of the host. METHODS: Genes encoding three B. abortus effector proteins (BPE005, BPE275, and BPE123) of T4SS were cloned and the recombinant proteins were expressed and purified. The purified recombinant proteins were named rBPE005, rBPE275 and rBPE123. Then, the expressions of Th1- and Th2-related cytokine genes were analyzed in mice bone marrow-derived macrophages (BMDMs) after stimulation with rBPE005, rBPE275, and rBPE123. Furthermore, four apoptosis-associated genes (Caspase-3, Caspase-8, Bax, and Bcl-2) were also detected to explore the damage of the proteins to the cells. RESULTS: Expressions of all Th1- and Th2-related cytokine genes were induced with three proteins, and different cytokine expression patterns induced by each protein depend on the stimulation time and dose of protein. However, expressions of apoptosis-related genes did not change. CONCLUSION: These results showed that the secreted antigens of Brucella induced an immune reaction via the production of Th1- and Th2-type cytokines in BMDMs without exerting any damage on the cells.
Subject(s)
Apoptosis , Bacterial Proteins , Cytokines , Macrophages , Recombinant Proteins , Type IV Secretion Systems , Animals , Macrophages/immunology , Macrophages/metabolism , Mice , Cytokines/metabolism , Type IV Secretion Systems/genetics , Bacterial Proteins/genetics , Bacterial Proteins/immunology , Mice, Inbred BALB C , Brucella abortus/immunology , Brucellosis/immunology , Brucellosis/genetics , Female , Brucella/immunology , Th1 Cells/immunologyABSTRACT
Glycoconjugate vaccines elicit robust anti-polysaccharide Ab response by recruiting T-cell help. Multiple doses of glycoconjugate vaccine are required to induce long-lasting immunity. The characteristics of anti-polysaccharide Ab response have been reported previously. However, the effect of glycoconjugate booster immunization on anti-polysaccharide and anti-carrier protein Ab repertoire remains poorly understood. In this study, we used clinically relevant pneumococcal capsular polysaccharide type 14 (PCP14) conjugated with cross-reactive material 197 (CRM197) as a model glycoconjugate Ag (PCP14-CRM197). We performed a comprehensive sequence analysis of mouse mAbs generated against PCP14 and CRM197 following immunization with one or three doses of PCP14-CRM197. Analysis of the paired Ig H and L chain transcripts revealed that anti-PCP14 Ab repertoire is extremely restricted. The reoccurrence of five replacement mutations at identical positions in anti-polysaccharide mAbs generated from different mice provided evidence for Ag-driven selection in PCP14-specific B cells. Convergent evolution was observed wherein distinct V(D)J rearrangements resulted in identical or nearly identical CDR3 in anti-PCP14 mAbs. Abs that lacked DH encoded amino acids dominated the anti-PCP14 Ab response. In contrast, anti-CRM197 Ab response was quite diverse, with fewer mutations compared with the anti-PCP14 mAbs, suggesting that conjugation of the polysaccharide to a carrier protein interferes with the development of carrier protein-specific Ab responses. Our findings provide molecular insights into the maturation of Ab responses driven by booster doses of glycoconjugate. This has fundamental implications for the design of glycoconjugate vaccines, especially where the development of Ab response against the carrier protein is also crucial.
Subject(s)
Antibodies, Bacterial , B-Lymphocytes , Bacterial Proteins , Glycoconjugates , Animals , Mice , Glycoconjugates/immunology , B-Lymphocytes/immunology , Bacterial Proteins/immunology , Bacterial Proteins/genetics , Antibodies, Bacterial/immunology , Antibodies, Monoclonal/immunology , Vaccines, Conjugate/immunology , Vaccines, Conjugate/administration & dosage , Female , Polysaccharides, Bacterial/immunology , Pneumococcal Vaccines/immunology , Pneumococcal Vaccines/administration & dosage , Streptococcus pneumoniae/immunology , Mice, Inbred BALB C , Antigens, Bacterial/immunology , Immunization/methods , Immunization, SecondaryABSTRACT
Helicobacter pylori (H. pylori) is responsible for various chronic or acute diseases, such as stomach ulcers, dyspepsia, peptic ulcers, gastroesophageal reflux, gastritis, lymphoma, and stomach cancers. Although specific drugs are available to treat the bacterium's harmful effects, there is an urgent need to develop a preventive or therapeutic vaccine. Therefore, the current study aims to create a multi-epitope vaccine against H. pylori using lipid nanoparticles. Five epitopes from five target proteins of H. pylori, namely, Urease, CagA, HopE, SabA, and BabA, were used. Immunogenicity, MHC (Major Histocompatibility Complex) bonding, allergenicity, toxicity, physicochemical analysis, and global population coverage of the entire epitopes and final construct were carefully examined. The study involved using various bioinformatic web tools to accomplish the following tasks: modeling the three-dimensional structure of a set of epitopes and the final construct and docking them with Toll-Like Receptor 4 (TLR4). In the experimental phase, the final multi-epitope construct was synthesized using the solid phase method, and it was then enclosed in lipid nanoparticles. After synthesizing the construct, its loading, average size distribution, and nanoliposome shape were checked using Nanodrop at 280 nm, dynamic light scattering (DLS), and atomic force microscope (AFM). The designed vaccine has been confirmed to be non-toxic and anti-allergic. It can bind with different MHC alleles at a rate of 99.05%. The construct loading was determined to be about 91%, with an average size of 54 nm. Spherical shapes were also observed in the AFM images. Further laboratory tests are necessary to confirm the safety and immunogenicity of the multi-epitope vaccine.
Subject(s)
Bacterial Vaccines , Computational Biology , Helicobacter pylori , Nanoparticles , Helicobacter pylori/immunology , Nanoparticles/chemistry , Bacterial Vaccines/immunology , Bacterial Vaccines/chemistry , Computational Biology/methods , Humans , Bacterial Proteins/immunology , Bacterial Proteins/chemistry , Epitopes/immunology , Epitopes/chemistry , Molecular Docking Simulation , Antigens, Bacterial/immunology , Antigens, Bacterial/chemistry , Helicobacter Infections/prevention & control , Helicobacter Infections/immunology , Toll-Like Receptor 4/immunology , Urease/immunology , Urease/chemistry , Immunoinformatics , LiposomesABSTRACT
OBJECTIVES: To assess the utility of Helicobacter pylori antibody testing, we evaluated the correlation between the H. pylori antibody titre and H. pylori-associated pathogenicity and the changes in antibody titre after H. pylori eradication therapy. DESIGN: A retrospective observational cohort study. SETTING AND PARTICIPANTS: From 2004 to 2016, medical check-ups were performed in different regions of Japan. In total, 324 subjects infected with H. pylori who received H. pylori eradication therapy were enrolled; H. pylori was eradicated in 266 of these subjects. We examined the associations between H. pylori antibody titre with pepsinogen and the presence or absence of H. pylori-associated pathogenic proteins, such as cytotoxin-associated gene A and vacuolating cytotoxin gene A, at baseline and after H. pylori eradication therapy. RESULTS: The H.pylori antibody titre showed a positive correlation with pepsinogen II and a negative correlation with the pepsinogen I/II ratio. Moreover, the H.pylori antibody titre significantly correlated with the positive rates of H. pylori-associated pathogenic protein before eradication therapy. Antibody titres decreased after eradication, the pepsinogen I/II ratio increased and the H. pylori-associated pathogenic protein-positive rate decreased in patients with successful eradication. The determination of eradication using the decline in antibody titre 6 months after eradication therapy was useful (area under the receiver operating characteristic curve: 0.98). CONCLUSIONS: Our data indicate that the H. pylori antibody titre may represent the degree of pathogenicity. The H. pylori antibody titre was associated with attenuation of pathogenicity in patients with H. pylori eradication, indicating the clinical utility of H. pylori antibody testing.
Subject(s)
Antibodies, Bacterial , Helicobacter Infections , Helicobacter pylori , Pepsinogen A , Humans , Helicobacter pylori/immunology , Retrospective Studies , Helicobacter Infections/drug therapy , Helicobacter Infections/immunology , Helicobacter Infections/microbiology , Male , Female , Japan , Antibodies, Bacterial/blood , Middle Aged , Aged , Pepsinogen A/blood , Adult , Anti-Bacterial Agents/therapeutic use , Bacterial Proteins/immunology , Pepsinogen C/blood , Antigens, Bacterial/immunologyABSTRACT
Pseudomonas plecoglossicida, a gram-negative bacterium, is the main pathogen of visceral white-point disease in marine fish, responsible for substantial economic losses in the aquaculture industry. The FliL protein, involved in torque production of the bacterial flagella motor, is essential for the pathogenicity of a variety of bacteria. In the current study, the fliL gene deletion strain (ΔfliL), fliL gene complement strain (C-ΔfliL), and wild-type strain (NZBD9) were compared to explore the influence of the fliL gene on P. plecoglossicida pathogenicity and its role in host immune response. Results showed that fliL gene deletion increased the survival rate (50%) and reduced white spot disease progression in the hybrid groupers. Moreover, compared to the NZBD9 strain, the ΔfliL strain was consistently associated with lower bacterial loads in the grouper spleen, head kidney, liver, and intestine, coupled with reduced tissue damage. Transcriptomic analysis identified 2 238 differentially expressed genes (DEGs) in the spleens of fish infected with the ΔfliL strain compared to the NZBD9 strain. Based on Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis, the DEGs were significantly enriched in seven immune system-associated pathways and three signaling molecule and interaction pathways. Upon infection with the ΔfliL strain, the toll-like receptor (TLR) signaling pathway was activated in the hybrid groupers, leading to the activation of transcription factors (NF-κB and AP1) and cytokines. The expression levels of proinflammatory cytokine-related genes IL-1ß, IL-12B, and IL-6 and chemokine-related genes CXCL9, CXCL10, and CCL4 were significantly up-regulated. In conclusion, the fliL gene markedly influenced the pathogenicity of P. plecoglossicida infection in the hybrid groupers. Notably, deletion of fliL gene in P. plecoglossicida induced a robust immune response in the groupers, promoting defense against and elimination of pathogens via an inflammatory response involving multiple cytokines.
Subject(s)
Fish Diseases , Pseudomonas Infections , Pseudomonas , Animals , Fish Diseases/immunology , Fish Diseases/microbiology , Fish Diseases/genetics , Pseudomonas/pathogenicity , Pseudomonas Infections/immunology , Pseudomonas Infections/veterinary , Pseudomonas Infections/microbiology , Bass/immunology , Bass/microbiology , Bass/genetics , Bacterial Proteins/genetics , Bacterial Proteins/immunology , Host-Pathogen Interactions/immunology , Host-Pathogen Interactions/genetics , Transcriptome , Gene Expression Profiling , Fish Proteins/genetics , Fish Proteins/immunologyABSTRACT
Antimicrobial resistance (AMR) poses a significant threat to human health. Although vaccines have been developed to combat AMR, it has proven challenging to associate specific vaccine antigens with AMR. Bacterial plasmids play a crucial role in the transmission of AMR. Our recent research has identified a group of bacterial plasmids (specifically, IncHI plasmids) that encode large molecular mass proteins containing bacterial immunoglobulin-like domains. These proteins are found on the external surface of the bacterial cells, such as in the flagella or conjugative pili. In this study, we show that these proteins are antigenic and can protect mice from infection caused by an AMR Salmonella strain harboring one of these plasmids. Furthermore, we successfully generated nanobodies targeting these proteins, that were shown to interfere with the conjugative transfer of IncHI plasmids. Considering that these proteins are also encoded in other groups of plasmids, such as IncA/C and IncP2, targeting them could be a valuable strategy in combating AMR infections caused by bacteria harboring different groups of AMR plasmids. Since the selected antigens are directly linked to AMR itself, the protective effect extends beyond specific microorganisms to include all those carrying the corresponding resistance plasmids.
Subject(s)
Drug Resistance, Bacterial , Plasmids , Animals , Plasmids/genetics , Mice , Drug Resistance, Bacterial/genetics , Bacterial Proteins/genetics , Bacterial Proteins/immunology , Bacterial Proteins/metabolism , Anti-Bacterial Agents/pharmacology , Single-Domain Antibodies/immunology , Single-Domain Antibodies/genetics , Single-Domain Antibodies/pharmacology , Antigens, Bacterial/immunology , Antigens, Bacterial/genetics , Female , Salmonella/genetics , Salmonella/immunology , Salmonella/drug effects , Immunoglobulins/genetics , Immunoglobulins/immunology , Mice, Inbred BALB CABSTRACT
Tuberculosis (TB) remains a significant global health challenge, with approximately 1.5 million deaths per year. The Bacillus Calmette-Guérin (BCG) vaccine against TB is used in infants but shows variable protection. Here, we introduce a novel approach using a double gene knockout mutant (DKO) from wild-type Mycobacterium tuberculosis (Mtb) targeting fbpA and sapM genes. DKO exhibited enhanced anti-TB gene expression in mouse antigen-presenting cells, activating autophagy and inflammasomes. This heightened immune response improved ex vivo antigen presentation to T cells. Subcutaneous vaccination with DKO led to increased protection against TB in wild-type C57Bl/6 mice, surpassing the protection observed in caspase 1/11-deficient C57Bl/6 mice and highlighting the critical role of inflammasomes in TB protection. The DKO vaccine also generated stronger and longer-lasting protection than the BCG vaccine in C57Bl/6 mice, expanding both CD62L-CCR7-CD44+/-CD127+ effector T cells and CD62L+CCR7+/-CD44+CD127+ central memory T cells. These immune responses correlated with a substantial ≥ 1.7-log10 reduction in Mtb lung burden. The DKO vaccine represents a promising new approach for TB immunization that mediates protection through autophagy and inflammasome pathways.
Subject(s)
Macrophages , Mice, Inbred C57BL , Mycobacterium tuberculosis , Tuberculosis Vaccines , Tuberculosis , Animals , Mycobacterium tuberculosis/immunology , Mice , Macrophages/immunology , Tuberculosis/immunology , Tuberculosis/prevention & control , Tuberculosis Vaccines/immunology , Antigens, Bacterial/immunology , Antigens, Bacterial/genetics , Inflammasomes/immunology , Female , BCG Vaccine/immunology , Autophagy/immunology , Bacterial Proteins/immunology , Bacterial Proteins/genetics , Disease Models, AnimalABSTRACT
The eradication of tuberculosis remains a global challenge. Despite being the only licensed vaccine, Bacillus Calmette-Guérin (BCG) confers limited protective efficacy in adults and individuals with latent tuberculosis infections (LTBI). There is an urgent need to develop novel vaccines that can enhance the protective effect of BCG. Protein subunit vaccines have garnered significant research interest due to their safety and plasticity. Based on previous studies, we selected three antigens associated with LTBI (Rv2028c, Rv2029c, Rv3126c) and fused them with an immunodominant antigen Ag85A, resulting in the construction of a multistage protein subunit vaccine named A986. We evaluated the protective effect of recombinant protein A986 adjuvanted with MPL/QS21 as a booster vaccine for BCG against Mycobacterium tuberculosis (Mtb) infection in mice. The A986 + MPL/QS21 induced the secretion of antigen-specific Th1 (IL-2+, IFN-γ+ and TNF-α+) and Th17 (IL-17A+) cytokines in CD4+ and CD8+ T cells within the lung and spleen of mice, while also increased the frequency of central memory and effector memory T cells. Additionally, it also induced the enhanced production of IgG antibodies. Compared to BCG alone, A986 + MPL/QS21 boosting significantly augmented the proliferation of antigen-specific multifunctional T cells and effectively reduced bacterial load in infected mice. Taken together, A986 + MPL/QS21 formulation induced robust antigen-specific immune responses and provided enhanced protection against Mtb infection as a booster of BCG vaccine.
Subject(s)
Antigens, Bacterial , BCG Vaccine , Cytokines , Mycobacterium tuberculosis , Tuberculosis , Vaccines, Subunit , Animals , Vaccines, Subunit/immunology , Mycobacterium tuberculosis/immunology , BCG Vaccine/immunology , Antigens, Bacterial/immunology , Female , Tuberculosis/prevention & control , Tuberculosis/immunology , Mice , Cytokines/metabolism , Immunization, Secondary , Disease Models, Animal , Adjuvants, Immunologic/administration & dosage , Tuberculosis Vaccines/immunology , Tuberculosis Vaccines/administration & dosage , Antibodies, Bacterial/blood , Antibodies, Bacterial/immunology , Mice, Inbred C57BL , Mice, Inbred BALB C , Acyltransferases/immunology , Lung/immunology , Lung/microbiology , Lung/pathology , Bacterial Proteins/immunology , HumansABSTRACT
Fish nocardiosis is a chronic disease mainly caused by Nocardia seriolae, which occurs in a variety of economically cultured freshwater and marine fish. Studies have shown that DNA vaccine is an effective treatment to protect fish from bacterial infection. In our previous experiment, an in vivo-induced gene of N. seriolae, encoding phosphoketolase (PK) family protein, was identified by in vivo-induced antigen technology. In the present study, the antigenic gene encoding PK family protein was analyzed by bioinformatics and further inserted into the eukaryotic expression vector pcDNA3.1-myc-his-A for DNA vaccine development. The immunological effects of pcDNA-PK DNA vaccine were assessed in hybrid snakehead (Channa maculata â × Channa argus â), showing induction in several serum enzyme activity parameters (including LZM, SOD, ACP and AKP), increasing in specific-antibody IgM levels, as well as up-regulation in six immune-related genes (CD4, CD8α, TNFα, IL-1ß, MHCIα and MHCIIα). Moreover, an immune-protection with a relative survival rate was provided at 53.82 % following artificial challenge with N. seriolae in vaccinated fish in comparison to the control group. In summary, these results indicate that pcDNA-PK DNA vaccine could boost strong immune responses in hybrid snakehead and show preferably protective efficacy against N. seriolae, which may be applied in aquaculture to control fish nocardiosis.
Subject(s)
Bacterial Vaccines , Fish Diseases , Nocardia Infections , Nocardia , Vaccines, DNA , Animals , Nocardia/immunology , Nocardia Infections/veterinary , Nocardia Infections/immunology , Nocardia Infections/prevention & control , Fish Diseases/immunology , Fish Diseases/prevention & control , Vaccines, DNA/immunology , Bacterial Vaccines/immunology , Aldehyde-Lyases/genetics , Aldehyde-Lyases/immunology , Fishes/immunology , Bacterial Proteins/immunology , Bacterial Proteins/geneticsABSTRACT
INTRODUCTION: Shigellosis is a gastrointestinal disease causes high morbidity and mortality worldwide, however, there is no anti-Shigella vaccine. The use of antibiotics in shigellosis treatment exacerbates antibiotic resistance. Antibodies, particularly egg yolk antibody (IgY), offer a promising approach to address this challenge. This study aimed to investigate the prophylactic effect of IgY produced against a recombinant chimeric protein containing the immunogens IpaD, IpaB, StxB, and VirG from Shigella. METHODS: The chimeric protein, comprising IpaD, IpaB, StxB, and VirG, was expressed in E. coli BL21 and purified using the Ni-NTA column. Following immunization of chickens, IgY was extracted from egg yolk using the PEG-6000 method and analyzed through SDS-PAGE and ELISA techniques. Subsequently, the prophylactic efficacy of IgY was assessed by challenging of mice with 10 LD50 of S. dysenteriae and administering different concentrations of IgY (1.25, 2.5, 5, and 10â¯mg/kg) under various time conditions. RESULTS: The recombinant protein, weighing 82â¯kDa, was purified and confirmed by western blotting. The IgY concentration was determined as 9.5â¯mg/ml of egg yolk and the purity of the extracted IgY was over 90â¯%. The results of the ELISA showed that at least 19â¯ng of pure antibody identified recombinant protein and reacts with it. The challenge test employing IgY and Shigella demonstrated a direct correlation between the survival rate and antibody concentration, with increased concentrations leading to decreased mortality rates. Treatment of mice with 10â¯mg/kg IgY leads to 80â¯% survival of the mice against 10 LD50 S. dysenteriae. CONCLUSION: Our findings suggest that IgY may offer therapeutic potential in treating Shigella infections and combating antibiotic resistance.
Subject(s)
Chickens , Dysentery, Bacillary , Egg Yolk , Immunoglobulins , Animals , Immunoglobulins/immunology , Mice , Egg Yolk/immunology , Dysentery, Bacillary/prevention & control , Dysentery, Bacillary/immunology , Shigella/immunology , Bacterial Proteins/immunology , Recombinant Proteins/immunology , Female , Antibodies, Bacterial/immunology , Mice, Inbred BALB C , Antigens, Bacterial/immunology , Recombinant Fusion Proteins/immunology , Recombinant Fusion Proteins/pharmacologyABSTRACT
Shigella bacteria utilize the type III secretion system (T3SS) to invade host cells and establish local infection. Invasion plasmid antigen D (IpaD), a component of Shigella T3SS, has garnered extensive interest as a vaccine target, primarily due to its pivotal role in the Shigella invasion, immunogenic property, and a high degree of conservation across Shigella species and serotypes. Currently, we are developing an epitope- and structure-based multivalent vaccine against shigellosis and require functional epitope antigens of key Shigella virulence determinants including IpaD. However, individual IpaD B-cell epitopes, their contributions to the overall immunogenicity, and functional activities attributing to bacteria invasion have not been fully characterized. In this study, we predicted continuous B-cell epitopes in silico and fused each epitope to a carrier protein. Then, we immunized mice intramuscularly with each epitope fusion protein, examined the IpaD-specific antibody responses, and measured antibodies from each epitope fusion for the activity against Shigella invasion in vitro. Data showed that all epitope fusion proteins induced similar levels of anti-IpaD IgG antibodies in mice, and differences were noted for antibody inhibition activity against Shigella invasion. IpaD epitope 1 (SPGGNDGNSV), IpaD epitope 2 (LGGNGEVVLDNA), and IpaD epitope 5 (SPNNTNGSSTET) induced antibodies significantly better in inhibiting invasion from Shigella flexneri 2a, and epitopes 1 and 5 elicited antibodies more effectively at preventing invasion of Shigella sonnei. These results suggest that IpaD epitopes 1 and 5 can be the IpaD representative antigens for epitope-based polyvalent protein construction and protein-based cross-protective Shigella vaccine development.IMPORTANCEShigella is a leading cause of diarrhea in children younger than 5 years in developing countries (children's diarrhea) and continues to be a major threat to public health. No licensed vaccines are currently available against the heterogeneous Shigella species and serotype strains. Aiming to develop a cross-protective multivalent vaccine against shigellosis and dysentery, we applied novel multiepitope fusion antigen (MEFA) technology to construct a broadly immunogenic polyvalent protein antigen, by presenting functional epitopes of multiple Shigella virulence determinants on a backbone protein. The functional IpaD epitopes identified from this study will essentially allow us to construct an optimal polyvalent Shigella immunogen, leading to the development of a cross-protective vaccine against shigellosis (and dysentery) and the improvement of global health. In addition, identifying functional epitopes from heterogeneous virulence determinants and using them as antigenic representatives for the development of cross-protective multivalent vaccines can be applied generally in vaccine development.
Subject(s)
Antigens, Bacterial , Epitopes, B-Lymphocyte , Shigella flexneri , Antigens, Bacterial/immunology , Antigens, Bacterial/genetics , Animals , Mice , Shigella flexneri/immunology , Shigella flexneri/genetics , Epitopes, B-Lymphocyte/immunology , Shigella Vaccines/immunology , Shigella Vaccines/administration & dosage , Shigella Vaccines/genetics , Dysentery, Bacillary/prevention & control , Dysentery, Bacillary/immunology , Dysentery, Bacillary/microbiology , Mice, Inbred BALB C , Epitope Mapping , Female , Shigella/immunology , Shigella/genetics , Bacterial Proteins/immunology , Bacterial Proteins/genetics , Antibodies, Bacterial/immunology , Antibodies, Bacterial/blood , Shigella sonnei/immunology , Shigella sonnei/genetics , Type III Secretion Systems/immunology , Type III Secretion Systems/geneticsABSTRACT
BACKGROUND: Enterococcus faecium and Staphylococcus aureus are the Gram-positive pathogens of the ESKAPE group, known to represent a great threat to human health due to their high virulence and multiple resistances to antibiotics. Combined, enterococci and S. aureus account for 26% of healthcare-associated infections and are the most common organisms responsible for blood stream infections. We previously showed that the peptidyl-prolyl cis/trans isomerase (PPIase) PpiC of E. faecium elicits the production of specific, opsonic, and protective antibodies that are effective against several strains of E. faecium and E. faecalis. Due to the ubiquitous characteristics of PPIases and their essential function within Gram-positive cells, we hypothesized a potential cross-reactive effect of anti-PpiC antibodies. RESULTS: Opsonophagocytic assays combined with bioinformatics led to the identification of the foldase protein PrsA as a new potential vaccine antigen in S. aureus. We show that PrsA is a stable dimeric protein able to elicit opsonic antibodies against the S. aureus strain MW2, as well as cross-binding and cross-opsonic in several S. aureus, E. faecium and E. faecalis strains. CONCLUSIONS: Given the multiple antibiotic resistances S. aureus and enterococci present, finding preventive strategies is essential to fight those two nosocomial pathogens. The study shows the potential of PrsA as an antigen to use in vaccine formulation against the two dangerous Gram-positive ESKAPE bacteria. Our findings support the idea that PPIases should be further investigated as vaccine targets in the frame of pan-vaccinomics strategy.
Subject(s)
Bacterial Proteins , Enterococcus faecalis , Enterococcus faecium , Peptidylprolyl Isomerase , Staphylococcus aureus , Staphylococcus aureus/immunology , Staphylococcus aureus/genetics , Enterococcus faecium/immunology , Enterococcus faecium/genetics , Bacterial Proteins/immunology , Bacterial Proteins/genetics , Peptidylprolyl Isomerase/immunology , Peptidylprolyl Isomerase/genetics , Enterococcus faecalis/immunology , Enterococcus faecalis/genetics , Humans , Gram-Positive Bacterial Infections/prevention & control , Gram-Positive Bacterial Infections/immunology , Gram-Positive Bacterial Infections/microbiology , Bacterial Vaccines/immunology , Opsonin Proteins/immunology , Antibodies, Bacterial/immunology , Antibodies, Bacterial/blood , Animals , Cross Reactions , Mice , Antigens, Bacterial/immunology , Antigens, Bacterial/genetics , Phagocytosis , Staphylococcal Infections/prevention & control , Staphylococcal Infections/immunology , Staphylococcal Infections/microbiologyABSTRACT
Yersinia pestis, the causative agent of plague and a biological threat agent, presents an urgent need for novel medical countermeasures due to documented cases of naturally acquired antibiotic resistance and potential person-to-person spread during a pneumonic infection. Immunotherapy has been proposed as a way to circumvent current and future antibiotic resistance. Here, we describe the development and characterization of two affinity matured human antibodies (αF1Ig AM2 and αF1Ig AM8) that promote survival of mice after exposure to aerosolized Y. pestis. We share details of the error prone PCR and yeast display technology-based affinity maturation process that we used. The resultant matured antibodies have nanomolar affinity for Y. pestis F1 antigen, are produced in high yield, and are resilient to 37°C stress for up to 6 months. Importantly, in vitro assays using a murine macrophage cell line demonstrated that αF1Ig AM2 and αF1Ig AM8 are opsonic. Even more importantly, in vivo studies using pneumonic plague mouse models showed that 100% of the mice receiving 500 µg of IgGs αF1Ig AM2 and αF1Ig AM8 survived lethal challenge with aerosolized Y. pestis CO92. Combined, these results provide evidence of the quality and robustness of αF1Ig AM2 and αF1Ig AM8 and support their development as potential medical countermeasures against plague.